GB:0RV2 Stock Latest News
Company AnnouncementsBioArctic Sets High-Influence Nomination Committee Ahead of 2027 AGM3d ago
Company AnnouncementsBioArctic and Eisai to Present Extensive New Lecanemab Data at CTAD 20263d ago
Company AnnouncementsBioArctic Royalty Surges on Strong Global Leqembi Sales5d ago- Company AnnouncementsBioArctic’s Leqembi Begins First Real-World Use in Sweden After EU Approval1M ago
Company AnnouncementsJapan Approves At-Home Leqembi Pen for Early Alzheimer’s Treatment1M ago
Company AnnouncementsBioArctic Partner Eisai Wins China Approval for At-Home Leqembi Alzheimer’s Autoinjector2M ago
Company AnnouncementsBioArctic Deepens Alzheimer’s Footprint With Leqembi Expansion and New Strategic Alliances2M ago
Company AnnouncementsBioArctic and Eisai Expand At-Home Alzheimer’s Treatment With U.S. Launch of Leqembi Iqlik2M ago
Pre-EarningsB9A Upcoming Earnings Report: What to Expect?2M ago
Company AnnouncementsBioArctic and Mesenkia team up on novel glioblastoma therapy2M ago
Company AnnouncementsBioArctic schedules August 26 webcast for Q2 2026 report2M agoCompany AnnouncementsReal-World Study Backs Long-Term Stability on BioArctic–Eisai Alzheimer’s Drug Leqembi3M ago
- Company AnnouncementsBioArctic’s Partner Eisai Wins FDA Nod for At-Home Leqembi Injection in Early Alzheimer’s3M ago
Company AnnouncementsSubcutaneous Leqembi Autoinjector Matches IV Exposure, Promises More Flexible Alzheimer’s Care3M ago- Company AnnouncementsBioArctic and Eisai to unveil expansive lecanemab data at AAIC 20264M ago
Company AnnouncementsBioArctic Taps Lilly in Fourth BrainTransporter Partnership4M ago
Company AnnouncementsBioArctic Updates Share and Vote Count After Stock Option Exercise5M agoCompany AnnouncementsBioArctic AGM Backs Dividend, New Share Mandate and Employee Incentive Plan5M ago
Company AnnouncementsEisai Sees Strong 2028 Sales Potential for BioArctic’s Alzheimer’s Drug Leqembi5M ago
